/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Alkermes plc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$29.29 0.0193(1.93%) ALKS at 04 Dec 2025 04:25 PM Drug Manufacturers - Specialty & Generic
Lowest Today 28.99
Highest Today 30.04
Today’s Open 29.27
Prev. Close 28.97
52 Week High 36.45
52 Week Low 25.17
Day’s Range: Low 28.99 High 30.04
52-Week Range: Low 25.17 High 36.45
1 day return -
1 Week return -0.16
1 month return -2.83
3 month return +2.07
6 month return -6.38
1 year return -5.04
3 year return +15.71
5 year return +54.79
10 year return -

Institutional Holdings

BlackRock Inc 16.87

Vanguard Group Inc 11.21

T. Rowe Price Associates, Inc. 6.08

iShares Core S&P Small-Cap ETF 5.94

State Street Corp 4.97

Baker Bros Advisors LP 3.88

Renaissance Technologies Corp 3.52

Vanguard Total Stock Mkt Idx Inv 3.15

JPMorgan Chase & Co 2.93

RTW INVESTMENTS, LLC 2.84

T. Rowe Price Mid-Cap Value 2.59

Geode Capital Management, LLC 2.44

Vanguard Small Cap Index 2.42

iShares Russell 2000 ETF 2.37

T. Rowe Price US Mid-Cap Value Equity 2.32

American Century Companies Inc 2.22

Dimensional Fund Advisors, Inc. 1.88

PRIMECAP Management Company 1.76

venBio Select Advisor LLC 1.76

Holocene Advisors, LP 1.73

Avantis US Small Cap Value ETF 1.62

COMMODORE CAPITAL LP 1.48

Vanguard Small Cap Growth Index Inv 1.37

Bank of America Corp 1.31

T. Rowe Price U.S. Mid-Cap Val Eq Tr-D 1.28

Loomis, Sayles & Company LP 1.28

Charles Schwab Investment Management Inc 1.27

Nuveen, LLC 1.24

SPDR® S&P Biotech ETF 1.19

NORGES BANK 1.13

Vanguard Capital Opportunity Inv 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Fidelity Small Cap Index 0.99

SPDR® Portfolio S&P 600™ Sm Cap ETF 0.88

JPM US Mid Cap Growth-Composite 0.80

JPMorgan Mid Cap Growth I 0.80

Vanguard Explorer Inv 0.71

First Trust NYSE Arca Biotech ETF 0.68

T. Rowe Price Health Sciences 0.67

Vanguard Tax-Managed Small Cap Adm 0.65

Market Status

Strong Buy: 8

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4783.45 M

PB Ratio 2.7529

PE Ratio 14.4129

Enterprise Value 3732.38 M

Total Assets 2055.57 M

Volume 1454539

Company Financials

Annual Revenue FY24:1557632000 1557.6M, FY23:1590604000 1590.6M, FY22:1111795000 1111.8M, FY21:1173751000 1173.8M, FY20:1038756000 1038.8M

Annual Profit FY24:1312301000 1312.3M, FY23:1353696000 1353.7M, FY22:893687000 893.7M, FY21:569838000 569.8M, FY20:465852000 465.9M

Annual Net worth FY24:367070000 367.1M, FY23:214724000 214.7M, FY22:-158267000 -158.3M, FY21:-48169000 -48.2M, FY20:-110861000 -110.9M

Quarterly Revenue Q3/2025:394185000 394.2M, Q2/2025:390657000 390.7M, Q1/2025:306510000 306.5M, Q4/2024:429986000 430.0M, Q3/2024:378143000 378.1M

Quarterly Profit Q3/2025:342594000 342.6M, Q2/2025:341197000 341.2M, Q1/2025:257313000 257.3M, Q4/2024:367870000 367.9M, Q3/2024:315044000 315.0M

Quarterly Net worth Q3/2025:82761000 82.8M, Q2/2025:87098000 87.1M, Q1/2025:22464000 22.5M, Q4/2024:146503000 146.5M, Q3/2024:92381000 92.4M

Fund house & investment objective

Company Information Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Organisation Drug Manufacturers - Specialty & Generic

Employees 1800

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Richard F. Pops

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow